SiewertII型食管胃交界部腺癌的手术治疗  

Surgical treatment of Siewert H adenocarcinoma of the esophagogastric junction

作　　者：秦允生[1] 庄业忠[2] 杨捷生[1] 黄楚坚[1] 许强周[1] 黄棉生[2] 

机构地区：[1]汕头大学肿瘤医院胸外科,515031 [2]汕头大学肿瘤医院腹外科,515031

出　　处：《中华胃肠外科杂志》2012年第9期910-912,共3页Chinese Journal of Gastrointestinal Surgery

摘　　要：目的总结食管胃交界部腺癌（AEG）外科手术的治疗效果。方法回顾性分析2000年10月至2006年9月间汕头大学肿瘤医院手术治疗的185例AEG患者的临床资料．比较经胸和经腹途径手术治疗的效果和影响预后的因素。结果全组185例患者．经左胸途径手术治疗133例（经胸组），经腹手术52例（经腹组）。两组手术并发症发生率分别为10．5％（14／133）和11．5％（6／52）．差异无统计学意义（P=0．531）。术后1、3、5年生存率两组分别为83．9％、44．5％、32．9％和86．0％、38．0％、30．0％，差异无统计学意义（P=-0．758）。结论AEG患者选择经胸或经腹的手术方式应个体化。Objective To explore the outcomes after surgical treatment of esophagogastric junction carcinoma （EGJC）. Methods One hundred and eighty-five patients with EGJC undergoing surgery from October 2000 to September 2006 at the Cancer Hospital of Shantou University were reviewed retrospectively. The clinical outcomes were compared between transthoracic and transabdominal approach. Results Of the 185 patients, 133 underwent operation via transthoracic approach and 52 via transabdominal approach. The postoperative complication rates were 10.5 % （14/133） and 11.5% （6/52） and the 1-, 3-, 5-year overall survival rates were 83.9%, 44.5%, 32.9% and 86.0%, 38.0%, 30.0% in transthoracic and transabdominal groups respectively, and the difference were not statistically significant（both P〉0.05）. Conclusion Surgical approach should be individualized for EGCJ.

关 键 词：食管胃交界部腺癌 外科手术 预后 

分 类 号：R735.1[医药卫生—肿瘤]